AKT1 and esophageal cancer: Afuresertib, a potent ATP-competitive and specific Akt inhibitor, has been shown to have good tumor-suppressive effects on malignant pleural mesothelioma cells, but whether it is effective against esophageal cancer cells and its mechanism of action remain unclear [17].